… in 2019. QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the … N.V. entered into a research collaboration to apply Axiomer ® to fibrosis targets selected by Galapagos. Positive … trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, CEO of ProQR. “We are …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… Board (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the … 1/2 trial of QR-110, announcing the in vivo PoC for our Axiomer technology and the completion of the pre-clinical … programs and our novel RNA-editing technology, Axiomer ® . We are also thrilled with the spin out of Amylon …
… N.V. entered into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected … research collaboration with Galapagos, where the company’s Axiomer ® technology will be applied to certain fibrosis … partnering and other strategic relationships for the Axiomer ® platform in select therapeutic areas Entered into a …
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… X: Late-breaking clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be … PhD, Sr. scientist computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: … Western world have LCA10 because of this mutation. About Axiomer ® Technology Platform ProQR is pioneering a …